Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PSMA-PET CT Clear all
Enrolling by invitation No phase listed Observational

Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT

NCT07690306
View directory record Official record
Conditions
Prostate Cancer (Diagnosis)
Interventions
Not listed
Lead sponsor
Xiangya Hospital of Central South University
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

NCT04838626
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
[18F]CTT1057
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Phase 3 Interventional

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

NCT07200830
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
129
States / cities
Anchorage, Alaska • Bakersfield, California • Irvine, California + 106 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting No phase listed Observational

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

NCT07019844
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
West Los Angeles, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

68 Ga-PSMA for High Risk Prostate Cancer

NCT04614363
View directory record Official record
Conditions
Prostate Cancer, High Risk
Interventions
68Ga-PSMA
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
21 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 23, 2026, 2:23 AM EDT
Terminated Phase 2 Interventional

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

NCT06322576
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
177Lu-PNT2002
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Active, not recruiting Phase 3 Interventional

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

NCT03582774
View directory record Official record
Conditions
Recurrent Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Other · Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Not listed Phase 2 Interventional

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
Ebrahim Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 23, 2026, 2:23 AM EDT
Terminated Phase 2 Interventional Results available

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

NCT04176497
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-HBED-CC-PSMA
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Early Phase 1 Interventional

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

NCT04266392
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F]-DCFPyl Ligand
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Phase 1 Interventional Results available

PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

NCT04086966
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
[68Ga]PSMA-PET/MRI or PET/CT
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Phase 2 Interventional

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

NCT06067269
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PSMA PET and MRI in Gynecological Cancers

NCT03302156
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
PSMA-based 18F-DCFPyL PET tracer
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Phase 2 Interventional

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT05616650
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
18F-DCFPyL, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Phase 3 Interventional

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

NCT06235099
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
Copper Cu 64 PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
31
States / cities
Fullerton, California • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Phase 2 Interventional

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

NCT07285057
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Not applicable Interventional

Comprehensive Assessment of Cancer Theranostic Response

NCT06815354
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRAQinform Theranostics
Device
Lead sponsor
AIQ Solutions
Industry
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 23, 2026, 2:23 AM EDT
Terminated Phase 1 Interventional

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT05733351
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

NCT02673151
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 23, 2026, 2:23 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT02981368
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection, PET/CT imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 23, 2026, 2:23 AM EDT
Recruiting Phase 1 Interventional

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

NCT05562791
View directory record Official record
Conditions
Bladder Cancer
Interventions
[68Ga]PSMA, PET/CT imaging
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 23, 2026, 2:23 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT03800784
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 23, 2026, 2:23 AM EDT